Response to Comments: Prostate Cancer Detection with IsoPSA®

This document is a responses-to-comments article about the IsoPSA® prostate cancer detection test tied to draft policy DL39284 (presented 2022-06-21). It does not itself define coverage indications, limitations, frequency limits, or claim documentation; reviewers must consult DL39284 and the final policy for definitive coverage criteria and claim requirements.

"This article contains responses to comments regarding the IsoPSA® prostate cancer detection test and refers to the revised draft policy DL39284 presented on 2022-06-21; it does not itself establish..."

Sign up to see full coverage criteria, indications, and limitations.